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Abstract Osteosarcoma cell lines vary widely in their suscept-
ibility to natural killer (NK) cell lysis in vitro although it is still 
unclear why this occurs. In this study we investigated the 
expression of some cell adhesion molecules on osteosarcomas to 
determine which of these can modify the susceptibility to NK 
lysis and we also attempted to modulate the cytolytic suscept-
ibility of these targets with TNFa. We found that osteosarcoma 
lysis induced by NK cells correlates with different expression of 
the CD54 adhesion molecule on osteosarcomas and the increased 
susceptibility after TNFa treatment mostly depends on the 
expression of CD54 molecules on target cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Natural killer (NK) cells are one of the lytic effector cells 
present among human peripheral blood mononuclear popula-
tions, involved in the defence mechanism against tumor and 
virally infected cells. These elements are CD 16, CD56 positive, 
but lack CD3 which differentiates them from T cells and 
makes them capable of spontaneous target lysis [1]. 
Different studies demonstrated that susceptibility to NK 
cell lysis is inversely influenced by the level of HLA class I 
antigen on target cells [2-6] and also by intercellular adhesion 
molecules which play a role in the interaction between target 
and effector cells [7]. Cell adhesion to the target is essential in 
establishing leukocyte-mediated cytolysis so that lytic media-
tors secreted by the NK cells can maintain high concentra-
tions at the site of junction with the target [8]. 
Osteosarcomas are bone-derived malignant tumors with 
vigorously invading capacity. They are characterized by an 
active proliferation of undifferentiated, atypic and often mi-
totic osteoblastic cells [9-12]. Despite advances in surgical 
technique and the development of aggressive adjuvant chemo-
therapy, pulmonary metastasis is still the major cause of death 
in patients with osteosarcoma. 
To investigate the role of NK cells in the control of osteo-
sarcoma proliferation we evaluated the susceptibility of differ-
ent osteosarcoma cell lines to NK cytolytic activity in vitro. A 
considerable variability in susceptibility to lysis was observed 
and it is currently unclear why this occurs. 
In this study we investigated whether a different expression 
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of some cell adhesion molecules and their ligands on osteo-
sarcoma cells could determine a different susceptibility to NK 
lysis. In addition, we tested the effect of treatment with TNFa 
(a cytokine that plays an important role in pathophysiology of 
bone remodelling [13]) of osteosarcoma cells on susceptibility 
to NK cell lysis and also attempted to modulate the suscept-
ibility of target cells. 
We demonstrated that TNFa-treated osteosarcoma cells 
have an enhanced susceptibility to NK cell lysis which mostly 
depends on the increased expression of CD54 molecules on 
target cells. 
2. Materials and methods 
2.1. Effector cells 
Effector lymphocytes were separated from the peripheral blood of 
12 healthy human volunteers (mean age ± S.D. 30 ± 2 years) by density 
gradient centrifugation and depleted of monocytes by absorption to 
plastic. Lymphocytes were suspended in RPMI 1640 medium supple-
mented with 10% heat-inactivated FCS, 4 mM glutamine, gentamicin 
(200 iig/ml) and used in cytotoxicity testing. 
2.2. Target tumor cells 
HOS, Saos-2, MG-63, and U-2 OS human cell lines are bone tu-
mors with an undifferentiated osteoblastic-like phenotype [9-12]. All 
the cell lines were obtained from ATCC (Rockville, MD, USA). They 
grow as adherent cells and were routinely passaged in RPMI 1640 
medium supplemented with 10% heat-inactivated FCS, 4 mM gluta-
mine and gentamicin (200 ug/ml). Before use in the experiments, cells 
were detached from monolayers by brief exposure to a solution of 
trypsin-EDTA (Sigma, USA), washed twice and resuspended in the 
same medium. 
2.3. Immunofluorescence analysis 
We verified the expression on osteosarcoma lines of a large panel of 
human antigens: CDlla, b, c, CD18, LFA-2 (CD2), LFA-3 (CD58), 
ICAM-1 (CD54), ICAM-2(CD102), ICAM-3 (CD50), N-CAM 
(CD56), VLA 1-6 (CD49a-f) and CD29. 
CDllc, CD54, CD49b, c, f (Cymbus Bioscience Ltd., UK), CD2, 
CD56 (Becton Dickinson, USA), CD29 (Endogen, USA), CD49a (T 
Cell Diagnostic, USA), and CD49e (Immunotech, France) were com-
mercially available FITC- or PE-conjugated monoclonal antibodies 
(MoAb). CDlla (LFA-la, TS1/22 clone), CDllb (LM2/1 clone), 
CD18 (LFA-ip, TS1/18 clone), CD58 (TS2/9 clone), CD102 (KS128 
clone), and CD49d (KD4-13 clone) were obtained from culture super-
natants of hybridomas. 
Incubation of 2 X10° osteosarcoma cells with MoAb was performed 
for 30 min at 4°C, followed by the secondary antibody (goat anti-
mouse FITC immunoglobulin, 1:20 dilution, Becton Dickinson, USA) 
when the MoAb was not directly conjugated with fluorochrome. In-
cubation with 1:10 mouse normal serum (Dako, Denmark) was per-
formed to reduce non-specific binding. Negative control cells were 
only incubated with Ig isotype control and/or with FITC-conjugated 
goat anti-mouse Ig. 
Analysis was performed with flow cytometry using a FACStar plus 
cell-sorter (Becton Dickinson, USA) calibrated for fluorescence inten-
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sity measurements using FITC or PE microbead standards (Quantum 
26, Flow Cytometry Standard Corporation, PR) with assigned MESF 
values (molecules of equivalent soluble fluorochrome) [14-16]. 
2.4. Cytokine treatment 
Osteosarcoma cells (2X106) were incubated with rHu TNFcc (50 
ng/ml; Boehringer Mannheim, Germany) for 24 h; untreated cultures 
were used as controls. After incubation, osteosarcoma cells were de-
tached with trypsin-EDTA (Sigma, USA), washed twice and adjusted 
to the appropriate cell concentration using culture medium. Cell via-
bility was determined with the eosin dye exclusion test. 
2.5. Cytotoxicity assay 
After incubation with or without cytokines for 24 h, osteosarcoma 
cells (2X 106) were labelled with 100 u,Ci of 51Cr (specific activity 400-
1200 Ci/g) (NEN, Germany) for 1 h at 37°C with occasional shaking. 
Tumor cells were then washed three times with cold medium, centri-
fuged and resuspended at a concentration of 104/ml. 
Varying numbers of effector lymphocytes (from 5 X 105 to 5 X 103 in 
100 ul) were added to 50 ul of target cells (E/T ratios from 100/1 to 1/ 
1). Cells were seeded in triplicate in 96-well V-bottomed plates (Nunc, 
Denmark), incubated for 4 h at 37°C and centrifuged. 
Supernatant was harvested from each well using a collection system 
containing cellulose acetate absorption cartridges (Skatron, Norway) 
and counted in a gamma counter. 
The percentage of 61Cr release was calculated as: (experimental 
release—spontaneous release)/(maximum release—spontaneous re-
lease) X 100. Spontaneous release represents the radioactivity of the 
target cells alone and maximum release the radioactivity of target cells 
lysed with 1% Triton-XlOO. Spontaneous release was as high as 15% 
of maximum release [17]. 
2.6. Blocking assays 
For the blocking experiments, target cells (1 X 106/ml) were incu-
bated with different concentrations of CD54 MoAb (4 ug/ml; 0.02 ug/ 
ml; 0.008 ug/ml) for 30 min, immediately following incubation with 
51 Cr, while effector lymphocytes were incubated with CD 11 a/CD 18 
MoAb (4 u.g/ml) for 30 min, immediately before seeding. 
The cells were incubated in purified MoAb or hybridoma super-
natant and in medium alone. After incubation the cells were washed 
twice and used as targets and effector, respectively, for cytotoxicity 
assay. 
2.7. Statistical analysis 
The experimental data are expressed as means ± S.E.M. Statistical 
significance was tested using Student's Mest for paired data. The 
Statistics for Windows package was used to perform statistical anal-
yses. 
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Fig. 1. Natural killer cell cytolytic activity against human osteosar-
coma cell lines. Results are expressed as mean percentages ± S.E.M. 
Significant differences between HOS and Saos-2, U-2 OS, MG-63 
cells for effector/target cell ratios: 100/1 and 12/1, P<0.0002; 50/1 
and 6/1, P< 0.001; 25/1, P<0.02 . 
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Fig. 2. Expression of adhesion molecules on osteosarcoma cell lines. 
Results are expressed as fluorescence channel number 
means ± S.E.M. 
3. Results 
3.1. Characterization of osteosarcoma cells 
The susceptibility of the osteosarcoma cell lines to NK cell 
lysis varied considerably but NK cell lysis was greater in HOS 
cells than in the other lines (Fig. 1). 
Cytofluorimetric analysis of the expression of adhesion mol-
ecules showed that only HOS cells were strongly positive for 
CD54 (Fig. 2) while CD58 and CD56, CD29 and CD49b-e 
were expressed similarly on all the cell lines. In contrast, 
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Fig. 3. Cytolytic activity of NK cells against HOS osteosarcoma 
cells after treatment with different concentrations of CD54 monoclo-
nal antibody. Cytotoxicity assay was performed blocking CD54 on 
HOS cells with 4 |xg/ml (closed triangles and continuous line); 0.2 
Hg/ml (closed triangles and dashed line); 0.08 ug/ml (open triangles 
and dashed line). Results are expressed as the percentage of control 
lysis mediated by unblocked cells (one representative experiment). 
CD49a was present in all but MG-63 and CD49f in all but 
HOS cell lines (Fig. 2). 
All cell lines were negative for CD102, CD50, CDlla , b, c/ 
CD18 and CD2 (data not shown). 
To establish the relevance of CD54 adhesion molecule ex-
pression to cytolytic reaction, HOS cells were incubated with 
different concentrations of CD54 blocking antibodies prior to 
co-culture with effector lymphocytes. The inhibition of NK 
cytolytic activity against HOS cells decreased progressively 
with the dilution of CD54 monoclonal antibody used for 
blocking target cells (Fig. 3). The saturation of the receptor 
using 4 ug/ml of CD54 was confirmed by flow cytometry: no 
changes in MESF values were observed with increasing doses 
(8 ug/ml) of blocking antibody. Therefore we used 4 ug/ml of 
CD54 for the following blocking tests. 
In parallel experiments the physiological counter-receptor 
molecule (CD 11 a/CD 18) was blocked on effector lymphocytes 
before incubation with untreated HOS cells that are CD54 
negative. Cytolytic reaction was also performed co-culturing 
HOS target cells and lymphocytes after the treatment of each 
antigen on the respective cell. 
A progressive inhibition of NK cell lysis was obtained in all 
three co-culture conditions (Fig. 4) and was more evident 
when both antigens were blocked on the respective cell and 
was complete at a 6/1 effector/target cell ratio. 
3.2. Effect of TNFa incubation on osteosarcoma cells 
TNFoc incubation enhanced the susceptibility of the osteo-
sarcoma cell lines to NK cell lysis (Fig. 5a-d) to different 
degrees. The increase was most evident on Saos-2 targets. 
The optimal dose of interleukin and the time required to in-
duce a modified susceptibility to NK cell lysis were previously 
determined (data not shown). 
To determine the effects of TNFa incubation on the expres-
sion of CD54 antigen, which seemed potentially involved in 
the regulation of susceptibility to NK lysis, the expression of 
this surface molecule was studied. 
HOS (CD54+) and Saos-2, MG-63, U-2 OS (CD54") os-
teosarcoma cells were treated with TNFoc for 24 h. A consist-
ent up-regulation of CD54 expression on HOS cells (Fig. 6a) 
(about twofold from 460 229 ±57 924 to 1 059 380 ± 161438 
MESF, P < 0.02) and the expression of CD54 on the other 
osteosarcoma cell lines that did not constitutively present this 
molecule (MG-63: 332 033 ±64 775 MESF; U-2 OS: 
258424±73449 MESF; Saos-2: 69548 ± 11 563 MESF) was 
observed after TNFa treatment. 
The consistent increment of CD54 intensity was correlated 
with a significant increase in the susceptibility to lysis of HOS 
cells after TNFa treatment (P = 0.0001, Fig. 7a). Also MG-63 
U-2 OS (data not shown) and Saos-2 cells (P = 0.005, Fig. 7b) 
increased their susceptibility to lysis after TNFa treatment 
which was linked to the appearance of CD54 antigen (Fig. 
6b), even if in Saos-2 cells the intensity of antigen expression 
was the lowest among the three CD54 osteosarcoma cells and 
more than 15-fold lower than in HOS cells. 
To confirm whether the increased susceptibility to lysis by 
NK cells was a consequence of the increased expression of 
CD54 on TNFa-treated osteosarcoma cells, we selectively 
blocked this molecule on HOS and Saos-2 cells (selected be-
cause they represent the highest and lowest CD54 expression 
respectively). Treatment with CD54 antibody resulted in a 
significant inhibition of NK-mediated lysis of TNFa treated 
HOS and Saos-2 cells. 
Almost equally effective was the treatment of the CDlla / 
CD 18 counter-receptor molecule on effector lymphocytes, 
while combined treatment with CD54 and CD 11 a/CD 18 on 
the corresponding cell further decreased susceptibility to NK 
cell lysis, which was inhibited by at least 80% at 3/1 effector/ 
target cell ratio (data not shown). 
These results confirm that the enhanced NK susceptibility 
of TNFa-treated HOS and Saos-2 cells depends on the in-
creased or induced expression of CD54 antigen on target cells. 
4. Discussion 
This study shows that the different susceptibility of osteo-
sarcoma cells to NK cell lysis is correlated with the different 
expression of the CD54 adhesion molecule. 
We evaluated a large number of cell adhesion molecules 
including those previously described on osteosarcoma cells 
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Fig. 4. Cytolytic activity of NK cells against HOS osteosarcoma 
cells after treatment with CD54 and/or CD 11 a/CD 18 monoclonal 
antibodies. Cytotoxicity assay was performed blocking CD54 on 
HOS cells ( A ) , the counter-receptor CDlla/CD18 on lymphocytes 
(•) or both (■). Results are expressed as the percentage of control 
lysis mediated by unblocked cells (one representative experiment). 
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and those known to be important in spontaneous killing [18-
21]. These molecules are involved in immune recognition and 
may play a role in host recognition of transformed cells. 
We found that CD56 and CD58 are commonly expressed 
by osteosarcoma cells, so that variation in their expression 
does not seem to be related to differences in NK cell lysis 
susceptibility. 
The VLA antigens were of greater potential interest since 
this receptor system may be activated on cytolytic effector 
cells and on tumor cells by interaction with extracellular ma-
trix proteins such as laminin, collagen IV and fibronectin [22]. 
A variable expression of these antigens has been reported 
among tumor cell lines related to adhesive interaction with 
extracellular matrix and to tumor progression and spread 
[23]. In particular the absence of CD49a on MG-63 and 
CD49f on HOS may suggest a different ability of these two 
osteosarcoma cells to interact with collagen and laminin re-
spectively. 
No correlation of CD49d cell-mediated lysis susceptibility 
has been reported for different tumor cells [24,25]. The CD49d 
receptor does not seem fundamental in the interaction of 
bone-derived tumor cells with effector cells of the immune 
system for the development of a lytic response, because it is 
uniformly expressed on the osteosarcomas studied. A similarly 
uniform expression was also shown by HLA class I molecules 
(data not shown). Of all the receptors, only CD54 seems to be 
important in determining susceptibility to spontaneous NK 
cell lysis: the expression of CD54 correlated with NK suscept-
ibility and the three tumor lines that were resistant to lysis 
were also all CD54-negative. 
From our data it seems that low levels of CD54 expression 
are sufficient to achieve the susceptibility conferred by this 
ligand, since this molecule appeared to influence the vulner-
ability of the target cell line also at low levels of expression as 
in Saos-2 cells incubated with TNFa. 
The importance of this molecule in determining susceptibil-
ity to NK cell lysis was confirmed by blocking studies, where 
the elimination of the CD54 cell surface molecule on target 
cells or its counter-receptor molecule (CD 11 a/CD 18) on effec-
tor lymphocytes substantially inhibited NK lysis. These data 
are supported by several groups, which, in other experimental 
models, have described a marked inhibition of NK cell lysis 
by anti-CD54 and by anti-CD 11 a/CD 18 monoclonal antibod-
ies [24,25]. 
The poor inhibition with one or both antibodies at a 12/1 
effector/target cell ratio can be related to the high number of 
effector cells, involved in the recognition of targets. At these 
high density cell conditions other surface receptors with low 
affinity and/or density can be involved in the binding of NK 
cells to osteosarcoma targets. At an effector/target ratio below 
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Fig. 5. Natural killer cell cytolytic activity against human osteosarcoma cell lines before (continous lines) and after TNFa incubation (dashed 
lines). Results are expressed as mean percentages± S.E.M. Significant differences after TNFa treatment are indicated: *P<0.05, **P<0.01, 
**'P< 0.005. 
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12/1, which is more similar to the numerical ratios found in 
vivo, CD54 molecule expression seems to assume a predom-
inant role in target cell recognition. 
Furthermore, we demonstrated that incubation with TNFa 
up-regulated the CD54 antigen on HOS cells and induced the 
expression of this antigen on NK-resistant Saos-2 cells and in 
addition that CD54 modifications were correlated with the 
increase in target susceptibility to NK lysis. In these experi-
mental conditions the block of CD54 or of its natural ligand 
on the respective cells confirmed the inhibition of lysis. 
The relevance of this study to assess the susceptibility to 
NK cell lysis of fresh bone tumor cells depends on whether 
ligand expression in vivo is similar to that of the osteosarcoma 
cell lines examined. Some studies indicate that despite numer-
ous differences human osteosarcoma cell lines can provide an 
experimental model for investigating specific aspects of bone 
cell function. In fact, the integrin profiles of some osteosarco-
ma cell lines are representative of the distribution of these 
molecules on bone cells and in particular the a4 subunit of 
|31 integrin (CD49d) expressed by all primary osteosarcoma 
cells [18,21]. Using this molecule, cells can adhere to the en-
dothelial cell lining expressing VCAM-1 [26-28], penetrate 
through the endothelium, then extravasate to the parenchymal 
organs and form metastases. The CD49d/VCAM-l pathway is 
the best characterized adhesion molecule pair involved in 
metastatic spread of some malignancies. 
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Fig. 7. Increased susceptibility to NK-mediated lysis of HOS (a) 
and Saos-2 (b) cell lines following TNFa treatment. Correlation be-
tween CD54 expression (FCN = fluorescence channel number) and 
percentage of 51Cr release. 
While there is no evidence that CD54 is expressed in clinical 
specimens of bone tumors, the expression of this molecule 
might correlate with a poor prognosis in melanomas [29]. 
Approximately 40% of patients with osteosarcoma tumor 
develop pulmonary metastases despite the administration of 
adjuvant chemotherapy, and the disease-free interval has not 
improved in recent years probably due to the presence of 
drug-resistant tumor cells. The development of new forms of 
tailor-made therapy is important in the hope of eradicating 
drug-resistant cells. 
If the CD54 molecule also confers susceptibility to NK cell 
lysis in vivo and we can take advantage of local administra-
tion of TNFa for a positive modulation of the CD54 mole-
cule, then the assessment of tumor susceptibility after expo-
sure to chemotherapy would predict whether or not residual 
osteosarcoma cells would be susceptible to NK cell lysis and 
whether NK cells are candidates for adjuvant therapy. 
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Fig. 6. Immunofluorescence analysis of CD54 on HOS (a) and 
Saos-2 (b) cell lines before (gray histograms) or after TNFa treat-
ment (black histograms). Negative control is represented by the dot-
ted histograms. 
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